Time to first bleeding episode (days) · People with a haematological disorder
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with standard‐dose schedule (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with WHO grade 3 or 4 bleeding up to 30 days… compared with prophylactic platelet transfusions with standard‐dose schedule (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · People with a haematological disorder
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with prophylactic platelet transfusions with standard‐dose schedule (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with high‐dose schedule (moderate certainty).
1 finding from 1 review
Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Intervention not reported
Overall survival1 · Patients with advanced non‐small cell lung cancer
The intervention leads to lower overall survival1 (high certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival1 · Patients with advanced non‐small cell lung cancer
The intervention showed no clear difference in progression‐free survival1 (low certainty).
1 finding from 1 review
Intervention not reported
One‐year survival rate2 · Patients with advanced non‐small cell lung cancer
The intervention leads to higher one‐year survival rate2 (high certainty).
1 finding from 1 review
Intervention not reported
Objective response rate2 · Patients with advanced non‐small cell lung cancer
The intervention may leads to higher objective response rate2 (low certainty).
1 finding from 1 review
Intervention not reported
Quality of life3 · Patients with advanced non‐small cell lung cancer
1 finding from 1 review
Intervention not reported
Serious adverse events2,4 · Patients with advanced non‐small cell lung cancer
The intervention may leads to higher serious adverse events2,4 (low certainty).
1 finding from 1 review
RR 37.36 [10.66, 130.95]
1 study · 4 participants
Low
Intervention not reported
5‐ year OS · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention probably leads to lower 5‐ year OS (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year PFS · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention probably leads to lower 5‐year PFS (moderate certainty).
1 finding from 1 review